CTI BioPharma
CTIC
$9.09
Share price
0.00%
Change (1 day)
30.79%
Change (1 year)
Categories
CTI BioPharma (CTIC) - P/B ratio
P/B ratio as of April 2024 : -47.3
According to CTI BioPharma
's latest financial reports the company has a price-to-book ratio of -47.3.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
CTI BioPharma - P/B ratio (from 2001 to 2022)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2022-12-31 | -43.4 | -168.16% |
| 2021-12-31 | 63.7 | 942.66% |
| 2020-12-31 | 6.11 | 19.5% |
| 2019-12-31 | 5.11 | 535.84% |
| 2018-12-31 | 0.8035 | -88.77% |
| 2017-12-31 | 7.16 | -51.75% |
| 2016-12-31 | 14.8 | 103.87% |
| 2015-12-31 | 7.28 | -32.89% |
| 2014-12-31 | 10.8 | 66.79% |
| 2013-12-31 | 6.50 | 49.98% |
| 2012-12-31 | 4.33 | -45.72% |
| 2011-12-31 | 7.98 | -113.83% |
| 2010-12-31 | -57.7 | 61.02% |
| 2009-12-31 | -35.9 | 54065.86% |
| 2008-12-31 | -0.0662 | -92.61% |
| 2007-12-31 | -0.8957 | -64.05% |
| 2006-12-31 | -2.49 | 70.36% |
| 2005-12-31 | -1.46 | -79.19% |
| 2004-12-31 | -7.03 | 96.76% |
| 2003-12-31 | -3.57 | -165.34% |
| 2002-12-31 | 5.47 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 4.25 | -108.99% | 🇨🇭 Switzerland |
 Eli Lilly LLY | 64.1 | -235.56% | 🇺🇸 USA |
 Amgen AMGN | 23.2 | -149.13% | 🇺🇸 USA |
 Baxter BAX | 2.42 | -105.11% | 🇺🇸 USA |
 Incyte INCY | 2.24 | -104.73% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 3.09 | -106.52% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 1.92 | -104.07% | 🇮🇱 Israel |